Pfizer, Inc. (PFE)

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Earlier in May 2026, Pfizer reported strong Phase 2 data for its investigational 25‑valent pneumococcal conjugate vaccine in infants and secured a European Commission approval to expand HYMPAVZI’s use to hemophilia A and B patients with inhibitors aged 12 and older.

Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor...

Pfizer’s PFE stock declined a little more than 1% following its first-quarter 2026 results on May 5, despite beating estimates for both earnings and sales. Sales rose 2% on an operational basis while earnings declined 18% year over year. The stock declined despite a robust first-quarter ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc.